A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Clinical trial NCT04569032 · COMPLETED
Trial details
- NCT number
- NCT04569032
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-12
- Primary completion
- 2024-05-09
- Enrollment
- 82
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.